SS
HOWL icon

SBI Securities’s Werewolf Therapeutics HOWL Stock Holding History

SBI Securities’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67 Buy
80
+40
+100% +$27 ﹤0.01% 3514
2025
Q4 		$25 Sell
40
-1
-2% -$1 ﹤0.01% 3730
2025
Q3 		$81 Buy
41
+1
+3% +$1 ﹤0.01% 3579
2025
Q2 		$44 Hold
40
– – ﹤0.01% 3749
2025
Q1 		$39 Hold
40
– – ﹤0.01% 3708
2024
Q4 		$59 Buy
+40
New +$82 ﹤0.01% 3602

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities's HOWL Position: Q1 2026 in Review

SBI Securities increased its Werewolf Therapeutics (HOWL) stake by 100% in Q1 2026, buying an estimated $27 and bringing the position to 80 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

SBI Securities first reported a position in HOWL in Q4 2024 and has held it in 6 quarters since. The position peaked at $81 in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • SBI Securities held 80 shares of Werewolf Therapeutics worth $67 as of Q1 2026.
  • SBI Securities bought 40 Werewolf Therapeutics shares in Q1 2026, an estimated $27.
  • Werewolf Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3514 holding.
  • SBI Securities first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Werewolf Therapeutics position peaked at $81 in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.